Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored Sorafenib + Metronomic Cyclophosphamide in Advanced NET
NCT00605566Phase 2Completed
- Sponsor
- University Health Network
- Start
- Jan 2008
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in neuroendocrine tumors (NETs), sponsored by University Health Network. Primary endpoints: Objective Response Rate up to 7 years and Association Between p-Shift Changes and Treatment Efficacy up to 7 years. Started Jan 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT00605566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00605566.